Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 62Neoplasm Metastasis 9Ovarian Neoplasms 8Endometrial Neoplasms 6Neoplasms 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Prostatic Neoplasms 4Hereditary Sensory and Autonomic Neuropathies 4Carcinoma, Non-Small-Cell Lung 4Squamous Cell Carcinoma of Head and Neck 3Neoplasms by Site 3Colorectal Neoplasms 3Breast Diseases 3Advanced Breast Cancer 3Small Cell Lung Carcinoma 2Recurrence 2Melanoma 2Locally Advanced (Inoperable) or Metastatic Breast Cancer 2Head and Neck Neoplasms 2Uterine Neoplasms 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Unilateral Breast Neoplasms 1Stomach Neoplasms 1Spinocerebellar Degenerations 1Salivary Gland Neoplasms 1Multiple Endocrine Neoplasia Type 1 1Malignant Neoplasms of Female Genital Organs 1Lung Neoplasms 1

Interventions

Cyclophosphamide 25fludarabine 19Dexamethasone 17pembrolizumab 13Rituximab 12venetoclax 9Lenalidomide 9Gemcitabine 9Etoposide 9pomalidomide 8Vincristine 7glofitamab 6fludarabine phosphate 6carfilzomib 6Temozolomide 6obinutuzumab 5daratumumab 5Prednisone 5Nivolumab 5Doxorubicin 5Cisplatin 5Calcium Dobesilate 5Bortezomib 5zanubrutinib 4selinexor 4Immunotherapy, Adoptive 4Cytarabine 4Carboplatin 4Azacitidine 4ruxolitinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recurrence × Fulvestrant × 90 days × Clear all
NCT07062965 2026-05-06

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Pfizer

Phase 3 Recruiting
400 enrolled
Breast

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT05154487 2026-03-03

A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer

GOG Foundation

Phase 2 Active not recruiting
51 enrolled

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡